$1.70
0.59% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US03836J1025
Symbol
APRE

Aprea Therapeutics Inc Stock price

$1.70
+0.00 0.00% 1M
-1.73 50.44% 6M
-1.59 48.33% YTD
-1.52 47.21% 1Y
-17.30 91.05% 3Y
-561.30 99.70% 5Y
-408.30 99.59% 10Y
-408.30 99.59% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.01 0.59%
ISIN
US03836J1025
Symbol
APRE
Industry

Key metrics

Basic
Market capitalization
$9.4m
Enterprise Value
$-9.9m
Net debt
positive
Cash
$19.3m
Shares outstanding
5.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.3 | 113.2
EV/Sales
negative | negative
EV/FCF
0.7
P/B
0.6
Financial Health
Equity Ratio
86.0%
Return on Equity
-62.9%
ROCE
-90.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$1.3m | $82.6k
EBITDA
$-15.2m | $-17.9m
EBIT
$-15.3m | $-19.0m
Net Income
$-14.1m | $-8.2m
Free Cash Flow
$-13.3m
Growth (TTM | estimate)
Revenue
33.3% | -94.5%
EBITDA
-8.9% | -24.8%
EBIT
-9.0% | -32.6%
Net Income
-10.8% | 37.0%
Free Cash Flow
-0.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,186.0% | -21,604.9%
EBIT
-1,187.7%
Net
-1,096.3% | -9,886.2%
Free Cash Flow
-1,031.7%
More
EPS
$-2.4
FCF per Share
$-2.4
Short interest
1.3%
Employees
8
Rev per Employee
$190.0k
Show more

Is Aprea Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Aprea Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Aprea Therapeutics Inc forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Aprea Therapeutics Inc forecast:

Buy
89%
Hold
11%

Financial data from Aprea Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1.28 1.28
33% 33%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.29 6.29
10% 10%
491%
- Research and Development Expense 10 10
29% 29%
801%
-15 -15
9% 9%
-1,190%
- Depreciation and Amortization 0.02 0.02
100% 100%
2%
EBIT (Operating Income) EBIT -15 -15
9% 9%
-1,192%
Net Profit -14 -14
11% 11%
-1,100%

In millions USD.

Don't miss a Thing! We will send you all news about Aprea Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aprea Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about 12 hours ago
Early evidence of disease control was observed in the ongoing Phase 1 ACESOT-1051 trial, with three patients achieving stable disease in the 70 mg and 100 mg cohorts treated with the WEE1 inhibitor, APR-1051
Neutral
GlobeNewsWire
about 2 months ago
Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy
Neutral
GlobeNewsWire
3 months ago
ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial
More Aprea Therapeutics Inc News

Company Profile

Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wenji Bao in 2002 and is headquartered in Boston, MA.

Head office United States
CEO Oren Gilad
Employees 8
Founded 2002
Website www.aprea.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today